EVG.L Regulatory News (EVG)

5 August 2019

Evgen Pharma plc

 ("Evgen" or "the Company")

Research collaboration with King's College London and British Heart Foundation

Evgen Pharma (AIM: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announces its support for a new research collaboration between King's College London ("King's") and the British Heart Foundation (''BHF'') investigating how Evgen's SFX-01 can provide neurovascular protection in ischaemic stroke through Nrf2-regulated redox signalling.

The collaboration is being funded principally by the BHF as a PhD studentship. Evgen will supply SFX-01 to the project and has the right to negotiate a licence over any resultant intellectual property, on fair and reasonable preferential terms. If successful, the research will provide further insight into how SFX-01 mediates upregulation of Nrf2 in the blood-brain barrier endothelium, thereby enhancing neurovascular protection.

This work will build on the existing collaboration between Evgen and King's which has demonstrated vascular protection in murine models of ischaemic stroke.

Professor Giovanni Mann, Professor of Vascular Physiology at King's College London and supervisor for the project, commented: "We are delighted to be collaborating again with Evgen Pharma and believe this project will build on our existing collaboration which showed great promise for SFX-01 in both stroke and potentially wider neuropsychiatric complications.''

Steve Franklin, CEO of Evgen Pharma, said: ''We welcome the opportunity to continue working with Professor Mann in developing the opportunities for SFX-01 in neurology. Meanwhile, we look forward to our Phase IIb clinical data from SFX-01 in subarachnoid stroke which we will announce later this year."

Enquiries:

About Evgen Pharma plc

Evgen Pharma is a clinical stage drug development company whose lead programmes are in breast cancer and subarachnoid haemorrhage, a type of stroke. The Company's core technology is Sulforadex®, a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin. 

The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG. 

For further information, please visit: www.evgen.com